Indianapolis, IN, United States of America

Gerald E Gutowski

USPTO Granted Patents = 8 

Average Co-Inventor Count = 1.7

ph-index = 3

Forward Citations = 29(Granted Patents)


Company Filing History:


Years Active: 1976-1982

Loading Chart...
8 patents (USPTO):Explore Patents

Title: Gerald E Gutowski: Innovator in Pharmaceutical Research

Introduction

Gerald E Gutowski is a prominent inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of neoplasms. With a total of 8 patents to his name, Gutowski's work has had a substantial impact on cancer treatment methodologies.

Latest Patents

Among his latest patents, Gutowski has developed innovative treatments such as the use of VLB 3-(2-chloroethyl) carboxamide in treating neoplasms. This patent focuses on the corresponding 4-desacetyl derivative and salts thereof, which are useful in pharmaceutical dosage forms. Additionally, he has worked on Vinca alkaloid intermediates, specifically 3-Spiro-5'-oxazolidine-2',4'-dione derivatives of Vinca alkaloids, which serve as anti-tumor agents and intermediates in drug development.

Career Highlights

Gerald E Gutowski is associated with Eli Lilly and Company, a leading pharmaceutical firm known for its commitment to innovation and research. His work at Eli Lilly has allowed him to explore and develop groundbreaking treatments that address critical health challenges.

Collaborations

Throughout his career, Gutowski has collaborated with notable colleagues, including Jean C Miller and Allen S Katner. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical solutions.

Conclusion

Gerald E Gutowski's contributions to pharmaceutical research and his innovative patents underscore his role as a key figure in the fight against cancer. His work continues to inspire advancements in medical treatments and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…